By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Real-world applications for wearable medical technology are numerous. They are increasingly helping our elderly population easily check and report vitals. They are also anticipated to change diagnostic imaging and radiology.
Radiologists all over the world are searching for medical imaging technologies to adopt since they will change the standard and speed of healthcare delivery. There is a critical need for quick, affordable, and effective medical imaging technology as the COVID-19 pandemic exacerbates problems like radiologist shortages, increasing rates of burnout, and restricted access to clinical care.
Brazil medical imaging market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
InsCer Diagnostic Center is the first facility to perform a florbetaben (18F) PET scan in Brazil, according to Life Molecular Imaging and R2IBF.
In order to determine the density of beta-amyloid neuritic plaques in the brain during Positron Emission Tomography (PET) imaging in adult patients with cognitive impairment who are being assessed for Alzheimer’s disease (AD) and other causes of cognitive decline, florbetaben (18F) is a radioactive diagnostic agent.
According to Desiree Zouain, R2IBF’s Research & Development & Innovation Coordinator, “R2IBF believes that it is crucial for the development of nuclear medicine in Brazil to introduce diagnostic products for neurology.As a result, R2IBF has invested heavily in the development and distribution of new radiopharmaceuticals targeted at this field.
Life Molecular Imaging, stated, “Life Molecular Imaging continues to expand its manufacturing and distribution network into new markets and we are thrilled to work with our partners in Brazil.”
“The first patient scan using florbetaben (18F) in Brazil demonstrates our commitment to furthering our international reach and enhancing accessibility to beta-amyloid PET imaging and other future imaging biomarkers to advance the precision of clinical diagnosis in Alzheimer’s and other neurodegenerative diseases,” the company said.
Bayer Pharma AG’s molecular imaging research and development portfolio was purchased by Life Molecular Imaging (LMI, formerly Piramal Imaging). It is now a part of the Alliance Medical Group, which is a subsidiary of the Life Healthcare Group.
The Alliance Medical Group offers an integrated business that includes R&D facilities, a network of cyclotrons, radiopharmacies, and imaging facilities. LMI is concentrating on a crucial area of contemporary medicine by creating novel PET tracers for molecular imaging.
